Portland immunotherapy startup tops $10M in funding as it launches first clinical trial - (GeekWire via NewsPoints Desk)

  • Emmanuel Akporiaye, founder of Veana Therapeutics, said the start-up raised its first venture funding, a $542 000 seed round that brings its total funding to more than $10 million, reported GeekWire.

  • The funds will go toward the first clinical trial of Veana's oral drug candidate Vimo, a vitamin E derivative that could potentially make cancer immunotherapies more effective, the news source said.

  • Vimo stimulates the immune system to continue attacking the cells, making it an ideal treatment partner for checkpoint inhibitors, according to the news source.

  • Akporiaye also noted that the drug has not shown any sign of toxic side effects, like those common for chemotherapy.

  • The new clinical trial will study Vimo in combination with Merck & Co.'s checkpoint inhibitor Keytruda.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.